Study of SX-682 Plus Enzalutamide in Men With Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer

Clinical Trials, High Risk Prostate Cancer, Intermediate Risk Prostate Cancer, Low Risk Prostate Cancer

— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

NCT Number: NCT06228053
Phase: PHASE2
Trial Summary: The goal of this clinical trial is to study the combination of SX-682 plus enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC) who have failed abiraterone. – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Syntrix Biosystems, Inc.
Acronym: SYNERGY-201

Pin It on Pinterest